Lexaria Bioscience Corp. Reports Net Loss of $2.38 Million for Q2 2023
Revenue Stands at $93,150, with Gross Profit of $80,403 for the Quarter
Lexaria Bioscience Corp., (LEXX) a biotechnology company special izing in drug delivery technologies, released its unaudited consolidated financial statements for the quarter ended May 31, 2023. The company reported a net loss of $2.38 million for the quarter, compared to a net loss of $2.42 million for the same period in 2022. Despite challenges, the company achieved a revenue of $93,150 for the quarter, reflecting steady progress in its business operations.
Net Loss of $2.38 Million
During the three-month period ending May 31, 2023, Lexaria Bioscience Corp. reported a net loss of $2.38 million. This figure represents the difference between total expenses incurred and revenue generated during the period. The net loss has narrowed compared to the previous year, indicating the company's efforts in controlling expenses and optimizing its operations.
